A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Completed · Phase 2 · Has a placebo group

Conditions studied: Non-Alcoholic Fatty Liver Disease (NAFLD)

In brief

This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD. In addition, this study will evaluate the safety and tolerability of co administration of PF 05221304 and PF 06865571 along with the effects on selected pharmacodynamics (PD)/exploratory parameters, compared to administration of PF 05221304 alone, PF 06865571 alone, and placebo in adults with NAFLD.

Key facts

Study ID

NCT03776175

Run by

Pfizer

People needed

99

Starts

2019-01-04

Expected to finish

2019-10-11

Last updated by the study team

2020-09-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male subjects or female subjects of non childbearing potential
• Total body weight of >50 kg (110 lbs) and a BMI greater than or equal to 25 kg/m2
• Medical diagnosis of Type 2 Diabetes Mellitus (T2DM) being treated with no more than 1 acceptable oral antidiabetic drug OR Subjects without a diagnosis of T2DM that meet 2 or more of the following 5 criteria commonly associated with metabolic syndrome
• Fasting Plasma Glucose (FPG) greater than or equal to 100 mg/dL;
• Documentation of at least stage 1 hypertension or medical history of hypertension;
• Fasting serum HDL C <40 mg/dL for males and <50 mg/dL for females, or on pharmacological agents with explicit purpose to increase HDL-C;
• Fasting serum triglyceride (TG) greater than or equal to 150 mg/dL or on pharmacological agents with explicit purpose to decrease TG;
• Waist circumference greater than or equal to 40 inches (102 cm) for males and 35 inches (89 cm) for females.
• Liver fat greater than or equal to 8% measured by MRI PDFF

You may not qualify if…

• Subjects with acute or chronic medical or psychiatric condition.
• Subjects with any of the following clinical laboratory abnormalities:
• Fasting TG >400 mg/dL;
• AST, ALT, or GGT >2.0x ULN;
• Hemoglobin A1c (HbA1c) >7.0%;
• Fasting plasma glucose >270 mg/dL;
• Total bilirubin >1.5x ULN;
• Albumin < lower limit of normal (LLN);
• Platelet count <0.95x LLN;
• International normalized ratio (INR) greater than or equal to 1.3.
• A positive urine test for illicit drugs.
• History of regular alcohol consumption.
• Seated systolic BP>=160 mmHg and/or diastolic BP>=100 mmHg.
• Supine 12 lead ECG demonstrating a corrected QT (QTcF) interval >450 msec or a QRS interval >120 msec.
• Subjects with an estimated GFR <60 mL/min/1.73m2.
• Evidence or diagnosis of other forms of chronic liver diseases.
• Subjects with any of the following medical conditions:
• Any condition possibly affecting drug absorption (eg prior bariatric surgery, gastrectomy, ileal resection);
• Diagnosis of type 1 diabetes mellitus;
• History of congestive heart failure, unstable angina, myocardial infarction, stroke, or transient ischemic attack;
• Any malignancy not considered cured (except basal cell carcinoma and squamous cell carcinoma of the skin);
• Active placement of medical devices in/on thoracic or abdominal cavities such as pacemakers, defibrillators;
• Subjects with any anatomical or pathological abnormality that would either preclude or tend to confound the analysis of study data.
• Blood donation of approximately 1 pint or more within 60 days prior to dosing.
• Subjects taking prohibited concomitant medication(s) or those unwilling/unable to switch to permitted concomitant medication(s)

Where it is running

• Franco Felizarta, Md — Bakersfield, California, United States
• Westside Medical Associates of Los Angeles — Beverly Hills, California, United States
• ProSciento, Inc. — Chula Vista, California, United States
• National Research Institute - Wilshire — Los Angeles, California, United States
• Catalina Research Institute, LLC — Montclair, California, United States
• Floridian Clinical Research, LLC — Hialeah, Florida, United States
• Research Centers of America, LLC — Hollywood, Florida, United States
• Jacksonville Center for Clinical Research — Jacksonville, Florida, United States
• Pharmax Research Clinic — Miami, Florida, United States
• Omega Research Maitland — Orlando, Florida, United States
• Accel Research Sites — Orlando, Florida, United States
• Advanced Gastroenterology Associates, LLC — Palm Harbor, Florida, United States
• QPS-MRA, LLC-Main Office — South Miami, Florida, United States
• East-West Medical Research Institute — Honolulu, Hawaii, United States
• Midwest Institute for Clinical Research — Indianapolis, Indiana, United States
• Heartland Research Associates, LLC — Wichita, Kansas, United States
• L-MARC Research Center — Louisville, Kentucky, United States
• Clarity Clinical Research — East Syracuse, New York, United States
• High Point Clinical Trials Center — High Point, North Carolina, United States
• M3 Wake Research, Inc — Raleigh, North Carolina, United States
• Wake Gastroenterology — Raleigh, North Carolina, United States
• PMG Research of Wilmington, LLC — Wilmington, North Carolina, United States
• Sterling Research Group - Mt. Auburn — Cincinnati, Ohio, United States
• New Horizons Clinical Research — Cincinnati, Ohio, United States
• WR-Clinsearch, LLC — Chattanooga, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.